이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biofrontera 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO

Biofrontera 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Pilar de la Huerta Martinez	CFO & Member of Executive Board	2yrs	€369.00k	데이터 없음
Ludwig Lutter	Member of the Executive Board	3.5yrs	€435.65k	데이터 없음
Alexander Richardson	Head of UK Sales Team	6.3yrs	데이터 없음	데이터 없음
Matthias Naumann	Head of Sales & Marketing - Europe	4.7yrs	데이터 없음	데이터 없음
Montserrat Foguet	Managing Director of Biofrontera UK Ltd.	1.8yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

경험이 풍부한 관리: B8FK 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Humphrey Rang	Head of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Wilhelm Zours	Chairman of the Supervisory Board	2.8yrs	€44.00k	데이터 없음
Heikki Lanckriet	Member of the Supervisory Board	2.8yrs	€22.00k	데이터 없음
Helge Lubenow	Member of the Supervisory Board	2.8yrs	€47.00k	데이터 없음
Karlheinz Schmelig	Member of the Supervisory Board	2.8yrs	€28.00k	데이터 없음
Jorgen Tielmann	Vice-Chairman of the Supervisory Board	2.8yrs	€33.00k	데이터 없음
Karin Lergenmuller	Member of Supervisory Board	2.1yrs	€23.00k	데이터 없음

2.8yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: B8FK 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Biofrontera 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Biofrontera AG, Annual General Meeting, Aug 28, 2024

Biofrontera AG, Annual General Meeting, Jun 20, 2023

Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd

Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board

Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financial Officer

Biofrontera AG Appoints Paul Böckmann to Management Board

Recent updates

Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024

Biofrontera AG, Annual General Meeting, Aug 28, 2024

Investor sentiment deteriorates as stock falls 31%

First quarter 2024 earnings released: €0.04 loss per share (vs €1.05 loss in 1Q 2023)

Biofrontera AG to Report Q1, 2024 Results on May 31, 2024

Full year 2023 earnings released: €0.01 loss per share (vs €0.77 loss in FY 2022)

Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024

Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023

Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023

Biofrontera Launches Novel Belixos Active Care

Biofrontera AG to Report Q1, 2023 Results on May 31, 2023

Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial

Biofrontera AG, Annual General Meeting, Jun 20, 2023

Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd

Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022

Biofrontera AD Shares - Sponsored to Be Deleted from OTC Equity

Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board

Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financial Officer

Biofrontera AG to Report First Half, 2022 Results on Aug 23, 2022

Biofrontera AG Appoints Paul Böckmann to Management Board

Biofrontera AG to Report Q1, 2022 Results on May 17, 2022

Biofrontera AG Provides Earnings Guidance for the Year 2022

Biofrontera AG to Report Fiscal Year 2021 Results on Apr 28, 2022

Biofrontera AG Proposes Revenue Guidance for the Year 2022

Biofrontera AG Resigns Franca Ruhwedel as Member of the Supervisory Board

Biofrontera AG Decides to Delist ADS from Nasdaq

Biofrontera AG Announces Progress of Phase Iii Study for the Treatment of sBCC with Ameluz®

Forecast to breakeven in 2024

Biofrontera AG Enrolls First Patient to Phase IIb Clinical Study Evaluating Ameluz® / BF-RhodoLED® for Acne

Price target decreased to €5.50

No longer forecast to breakeven

Price target decreased to €5.50

No longer forecast to breakeven

Third quarter 2021 earnings released: €0.095 loss per share (vs €0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.001 loss in 2Q 2020)

Biofrontera AG Re-Affirms Earnings Guidance for the Year 2021

Biofrontera AG Provides Update on Clinical Developments

Price target increased to €6.80

First quarter 2021 earnings released: €0.09 loss per share (vs €0.14 loss in 1Q 2020)

Price target decreased to €6.90

Full year 2020 earnings released: €0.24 loss per share (vs €0.17 loss in FY 2019)

Biofrontera AG Provides Earnings Guidance for the Year 2021

Price target raised to €10.33

Biofrontera AG to Report Fiscal Year 2020 Final Results on Apr 12, 2021

CFO & Member of the Executive Board has left the company

Biofrontera AG Submits Study Report of Pharmacokinetics Study to FDA

New 90-day low: €2.88

Biofrontera AG Announces Management Changes

Price target raised to €8.55

New 90-day high: €3.50

Third quarter 2020 earnings released: €0.11 loss per share

New 90-day low: €2.91

Biofrontera AG Receives Reasons from the German Federal Court of Justice for Overturning Ruling of the Cologne Higher Regional Court

Biofrontera AG Reports Completion of the Clinical Phase of the Pharmacokinetics Study

Biofrontera AG Announces German Federal Supreme Court Overturns Ruling of the Cologne Higher Regional Court

Biofrontera AG(XTRA:B8F) dropped from S&P Global BMI Index

Price target raised to €7.77

Earnings released

Biofrontera AG announced that it has received €7.91445 million in funding

New 90-day high - €3.80

Biofrontera AG announced that it expects to receive €7.91445 million in funding

Biofrontera AG to Report First Half, 2020 Results on Aug 26, 2020

CEO

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령